Lataa...
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
BACKGROUND/AIMS: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. METHODS:...
Tallennettuna:
| Julkaisussa: | Clin Mol Hepatol |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Korean Association for the Study of the Liver
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7364362/ https://ncbi.nlm.nih.gov/pubmed/32460460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2019.0044n |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|